NCT05582538 - Restoring Sensitivity To Immunotherapy In Advanced Triple Negative Breast Cancer Exploiting Ceralasertib Priming Followed By Combined Durvalumab/Nab-Paclitaxel | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

December 15, 2022

Primary Completion Date

December 31, 2027

Study Completion Date

December 31, 2029

Conditions

Triple Negative Breast Cancer Metastatic

Interventions

DRUG

Ceralasertib

240mg orally BD (dose level 0) on days -6 to 0 prior to day 1 cycle 1 and then on days 22 to 28 of cycle 1 and every subsequent cycle

DRUG

Durvalumab

1500 mg i.v. day 1 (q28)

DRUG

Nab-paclitaxel

100mg/m2 i.v. day 1,8,15 (q28)

Trial Locations (6)

RECRUITING

ASST Papa Giovanni XXIII, Bergamo

RECRUITING

"IRCCS Istituto Nazionale Tumori Fondazione Giovanni Pascale", Napoli

RECRUITING

Azienda Ospedaliero Universitaria Maggiore della Carità, Novara

RECRUITING

Istituto Nazionale dei Tumori IRCCS, Milan

RECRUITING

Istituto Oncologico Veneto IRCCS, Padua

RECRUITING

Azienda U.S.L. - IRCCS di Reggio Emilia, Reggio Emilia